THAP7

Summary

THAP7 (THAP domain containing 7, HGNC:23190) is a protein-coding gene on chromosome 22q11.21, encoding THAP domain-containing protein 7 (Q9BT49). Chromatin-associated, histone tail-binding protein that represses transcription via recruitment of HDAC3 and nuclear hormone receptor corepressors.

Enables several functions, including C2H2 zinc finger domain binding activity; histone deacetylase binding activity; and transcription corepressor binding activity. Involved in chromatin organization and negative regulation of transcription by RNA polymerase II. Located in chromatin; nuclear membrane; and nuclear speck.

Source: NCBI Gene 80764 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 58 total — 4 pathogenic
• MANE Select transcript: NM_030573

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23190
Approved symbol	THAP7
Name	THAP domain containing 7
Location	22q11.21
Locus type	gene with protein product
Status	Approved
Aliases	MGC10963
Ensembl gene	ENSG00000184436
Ensembl biotype	protein_coding
OMIM	609518
Entrez	80764

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 6 retained_intron, 3 protein_coding

ENST00000215742, ENST00000399133, ENST00000466670, ENST00000471073, ENST00000471723, ENST00000476667, ENST00000488975, ENST00000498406, ENST00000917978

RefSeq mRNA: 2 — MANE Select: NM_030573 NM_001008695, NM_030573

CCDS: CCDS13787

Canonical transcript exons

ENST00000215742 — 4 exons

Exon	Start	End
ENSE00000879291	21001256	21001411
ENSE00001825528	21001832	21002118
ENSE00001899849	20999104	21000432
ENSE00003490417	21000647	21000787

Expression profiles

Bgee: expression breadth ubiquitous, 283 present calls, max score 94.96.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 33.2564 / max 437.8199, expressed in 1815 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
193219	19.9101	1794
193221	11.5331	1796
193220	0.9719	416
193218	0.4406	224
193217	0.4006	229

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adenohypophysis	UBERON:0002196	94.96	gold quality
pituitary gland	UBERON:0000007	94.01	gold quality
right testis	UBERON:0004534	92.90	gold quality
hindlimb stylopod muscle	UBERON:0004252	92.60	gold quality
left testis	UBERON:0004533	92.31	gold quality
apex of heart	UBERON:0002098	92.30	gold quality
mucosa of stomach	UBERON:0001199	91.82	gold quality
gastrocnemius	UBERON:0001388	91.56	gold quality
left uterine tube	UBERON:0001303	91.36	gold quality
right lobe of liver	UBERON:0001114	91.23	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	91.00	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	90.97	gold quality
muscle of leg	UBERON:0001383	90.92	gold quality
left ovary	UBERON:0002119	90.72	gold quality
endocervix	UBERON:0000458	90.70	gold quality
right ovary	UBERON:0002118	90.70	gold quality
muscle layer of sigmoid colon	UBERON:0035805	90.67	gold quality
left adrenal gland	UBERON:0001234	90.62	gold quality
right adrenal gland cortex	UBERON:0035827	90.62	gold quality
left adrenal gland cortex	UBERON:0035825	90.57	gold quality
right adrenal gland	UBERON:0001233	90.52	gold quality
body of stomach	UBERON:0001161	90.47	gold quality
adrenal cortex	UBERON:0001235	90.40	gold quality
lower esophagus muscularis layer	UBERON:0035833	90.39	gold quality
lower esophagus	UBERON:0013473	90.36	gold quality
testis	UBERON:0000473	90.34	gold quality
prefrontal cortex	UBERON:0000451	90.29	gold quality
body of uterus	UBERON:0009853	90.27	gold quality
right uterine tube	UBERON:0001302	89.57	gold quality
right lobe of thyroid gland	UBERON:0001119	89.55	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.13
E-MTAB-7606	no	1184.79

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

2 targets.

Target	Regulation
CDKN2A
NCOR1

miRNA regulators (miRDB)

12 targeting THAP7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-7106-5P	99.53	67.47	3574
HSA-MIR-183-5P	99.31	72.27	1164
HSA-MIR-6769B-5P	98.73	64.91	1092
HSA-MIR-6804-3P	98.72	64.82	852
HSA-MIR-6769A-5P	97.99	64.16	851
HSA-MIR-4456	97.50	64.88	1678
HSA-MIR-4654	95.86	65.72	751

Literature-anchored findings (GeneRIF, showing 2)

• demonstration of the transcriptional regulatory properties of a human THAP domain protein, and a critical identification of a potential transducer of the repressive signal of hypoacetylated histone H4 in higher eukaryotes (PMID:15561719)
• THAP7 may represent a novel class of transcription factor that uses TAF-Ibeta as a corepressor to maintain histones in a hypoacetylated, repressed state. (PMID:16195249)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	thap7	ENSDARG00000070704
mus_musculus	Thap7	ENSMUSG00000022760
rattus_norvegicus	Thap7	ENSRNOG00000037967
drosophila_melanogaster	CG13894	FBGN0035157

Paralogs (7): THAP3 (ENSG00000041988), THAP1 (ENSG00000131931), ARL14EP (ENSG00000152219), THAP8 (ENSG00000161277), THAP2 (ENSG00000173451), THAP6 (ENSG00000174796), ARL14EPL (ENSG00000268223)

Protein

Protein identifiers

THAP domain-containing protein 7 — Q9BT49 (reviewed: Q9BT49)

All UniProt accessions (1): Q9BT49

UniProt curated annotations — full annotation on UniProt →

Function. Chromatin-associated, histone tail-binding protein that represses transcription via recruitment of HDAC3 and nuclear hormone receptor corepressors.

Subunit / interactions. Forms homodimers. Interacts with HDAC3 and nuclear hormone receptor corepressors. Interacts via HBM with HCFC1.

Subcellular location. Nucleus. Chromosome.

RefSeq proteins (2): NP_001008695, NP_085050* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006612	THAP_Znf	Domain
IPR026519	THAP7	Family

Pfam: PF05485

UniProt features (8 total): modified residue 2, chain 1, zinc finger region 1, region of interest 1, short sequence motif 1, compositionally biased region 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BT49-F1	70.89	0.28

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 162, 210

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 112 (showing top): GOCC_NUCLEAR_SPECK, GOCC_NUCLEAR_BODY, GOCC_RIBONUCLEOPROTEIN_GRANULE, OSF2_Q6, GOMF_C2H2_ZINC_FINGER_DOMAIN_BINDING, GOMF_HISTONE_DEACETYLASE_BINDING, GOMF_TRANSCRIPTION_COREGULATOR_BINDING, GOMF_TRANSCRIPTION_FACTOR_BINDING, MARTENS_TRETINOIN_RESPONSE_DN, GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II, BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_B, GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS, MTF1_Q4, GOCC_SUPRAMOLECULAR_COMPLEX, GOMF_TRANSCRIPTION_COREPRESSOR_BINDING

GO Biological Process (4): negative regulation of transcription by RNA polymerase II (GO:0000122), chromatin organization (GO:0006325), regulation of DNA-templated transcription (GO:0006355), negative regulation of DNA-templated transcription (GO:0045892)

GO Molecular Function (11): transcription corepressor binding (GO:0001222), DNA binding (GO:0003677), zinc ion binding (GO:0008270), identical protein binding (GO:0042802), histone deacetylase binding (GO:0042826), C2H2 zinc finger domain binding (GO:0070742), histone H4 reader activity (GO:0140008), general transcription initiation factor binding (GO:0140296), histone reader activity (GO:0140566), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (6): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), nuclear speck (GO:0016607), nuclear membrane (GO:0031965), chromosome (GO:0005694)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
DNA-templated transcription	2
cellular anatomical structure	2
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
cellular component organization	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
regulation of DNA-templated transcription	1
negative regulation of RNA biosynthetic process	1
transcription coregulator binding	1
nucleic acid binding	1
transition metal ion binding	1
protein binding	1
enzyme binding	1
protein domain specific binding	1
histone reader activity	1
transcription factor binding	1
nucleosome	1
histone binding	1
chromatin-protein adaptor activity	1
binding	1
cation binding	1
chromosome	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
nuclear ribonucleoprotein granule	1
nucleus	1
nuclear envelope	1
organelle membrane	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

1332 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
THAP7	THAP11	Q96EK4	938
THAP7	THAP12	O43422	912
THAP7	THAP1	Q9NVV9	865
THAP7	H4C7	Q99525	756
THAP7	H4C16	P02304	751
THAP7	PI4KA	P42356	677
THAP7	NCOR1	O75376	675
THAP7	TAF1B	Q53T94	650
THAP7	AIFM3	Q96NN9	646
THAP7	SLC7A4	O43246	637
THAP7	SNAP29	O95721	589
THAP7	THAP4	Q8WY91	584
THAP7	LZTR1	Q8N653	583
THAP7	ZNF74	Q16587	575
THAP7	HDAC3	O15379	557

IntAct

228 interactions, top by confidence:

A	B	Type	Score
THAP7	TRAF2	psi-mi:“MI:0915”(physical association)	0.830
TRAF2	THAP7	psi-mi:“MI:0915”(physical association)	0.830
SET	THAP7	psi-mi:“MI:0915”(physical association)	0.810
THAP7	SET	psi-mi:“MI:0915”(physical association)	0.810
TFIP11	THAP7	psi-mi:“MI:0915”(physical association)	0.780
THAP7	TFIP11	psi-mi:“MI:0915”(physical association)	0.780
KRTAP10-8	THAP7	psi-mi:“MI:0915”(physical association)	0.720
TRAF1	THAP7	psi-mi:“MI:0915”(physical association)	0.720
THAP7	KRT31	psi-mi:“MI:0915”(physical association)	0.720
THAP7	LZTS2	psi-mi:“MI:0915”(physical association)	0.720
MID2	THAP7	psi-mi:“MI:0915”(physical association)	0.720
THAP7	MID2	psi-mi:“MI:0915”(physical association)	0.720
THAP7	KRTAP10-8	psi-mi:“MI:0915”(physical association)	0.720
THAP7	TRAF1	psi-mi:“MI:0915”(physical association)	0.720

BioGRID (136): THAP7 (Two-hybrid), THAP7 (Two-hybrid), THAP7 (Two-hybrid), THAP7 (Two-hybrid), THAP7 (Two-hybrid), THAP7 (Two-hybrid), THAP7 (Two-hybrid), THAP7 (Two-hybrid), THAP7 (Two-hybrid), THAP7 (Two-hybrid), THAP7 (Two-hybrid), THAP7 (Two-hybrid), LZTS2 (Two-hybrid), LNX1 (Two-hybrid), KRT40 (Two-hybrid)

ESM2 similar proteins: A0A0G2JXN2, A2RRU4, A4D2P6, A6QM06, D3YYI7, E1BBQ2, E9PGG2, F1LQY6, O19131, P19438, P29590, P50555, P52734, P55199, P97260, P98174, Q0VCT3, Q12770, Q3TAA7, Q3ZCA1, Q496Y0, Q4R4I0, Q5E9N3, Q5MNU5, Q5R5T1, Q60953, Q66T02, Q69Z89, Q6GQT6, Q70EL4, Q7TNM2, Q7Z4K8, Q7Z6J9, Q8BUM9, Q8C190, Q8CE64, Q8HXH0, Q8N1F8, Q8N554, Q8TC41

Diamond homologs: B5XCB8, Q0IHI7, Q0P5B4, Q1JPT7, Q1RMM0, Q2TBI2, Q3T0G1, Q4R3Q6, Q4R7M0, Q5RCE4, Q5U208, Q5U560, Q5ZHN5, Q642B6, Q6DDT6, Q6DIN8, Q6P3Z3, Q7Z6K1, Q8CHW1, Q8NA92, Q8VCZ3, Q8WTV1, Q8WY91, Q9BT49, Q9D305, Q9H0W7, Q9NVV9, Q8TBB0, Q9H5L6, Q8BJ25

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 53 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Keratinization	7	11.1×	6e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

58 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	4
Likely pathogenic	0
Uncertain significance	50
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (4)

Variant ID	HGVS	Classification
1321997	GRCh37/hg19 22q11.21(chr22:18884714-21483289)x1	Pathogenic
1808642	GRCh37/hg19 22q11.21(chr22:18644543-21800797)x1	Pathogenic
636285	GRCh37/hg19 22q11.21(chr22:18648855-21461017)x3	Pathogenic
929312	GRCh37/hg19 22q11.21(chr22:18886915-21463730)x1	Pathogenic

SpliceAI

642 predictions. Top by Δscore:

Variant	Effect	Δscore
22:21000433:C:CC	acceptor_gain	1.0000
22:21000643:ATAC:A	donor_loss	1.0000
22:21000644:TA:T	donor_loss	1.0000
22:21000645:A:AC	donor_gain	1.0000
22:21000645:ACCG:A	donor_gain	1.0000
22:21000645:ACCGC:A	donor_loss	1.0000
22:21000646:C:A	donor_loss	1.0000
22:21000646:C:CC	donor_gain	1.0000
22:21000646:CCG:C	donor_gain	1.0000
22:21000646:CCGC:C	donor_gain	1.0000
22:21000651:T:TA	donor_gain	1.0000
22:21000783:ATCCA:A	acceptor_gain	1.0000
22:21000784:TCCA:T	acceptor_gain	1.0000
22:21000785:CCA:C	acceptor_gain	1.0000
22:21000785:CCAC:C	acceptor_gain	1.0000
22:21000786:CA:C	acceptor_gain	1.0000
22:21000786:CAC:C	acceptor_gain	1.0000
22:21000788:C:CC	acceptor_gain	1.0000
22:21000788:CT:C	acceptor_loss	1.0000
22:21001283:T:TA	donor_gain	1.0000
22:21001412:C:CC	acceptor_gain	1.0000
22:21001828:TGACC:T	donor_loss	1.0000
22:21001830:A:C	donor_loss	1.0000
22:21001831:C:A	donor_loss	1.0000
22:21000429:GCAG:G	acceptor_gain	0.9900
22:21000430:CAG:C	acceptor_gain	0.9900
22:21000430:CAGC:C	acceptor_gain	0.9900
22:21000431:AG:A	acceptor_gain	0.9900
22:21000431:AGC:A	acceptor_loss	0.9900
22:21000432:GC:G	acceptor_loss	0.9900

AlphaMissense

1971 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
22:21000755:G:T	P90H	1.000
22:21000756:G:A	P90S	1.000
22:21000756:G:T	P90T	1.000
22:21001288:A:C	F68L	1.000
22:21001288:A:T	F68L	1.000
22:21001289:A:C	F68C	1.000
22:21001289:A:G	F68S	1.000
22:21001290:A:G	F68L	1.000
22:21001300:G:C	C64W	1.000
22:21001301:C:A	C64F	1.000
22:21001301:C:G	C64S	1.000
22:21001301:C:T	C64Y	1.000
22:21001302:A:G	C64R	1.000
22:21001302:A:T	C64S	1.000
22:21001304:A:G	F63S	1.000
22:21001308:A:C	Y62D	1.000
22:21001330:C:A	W54C	1.000
22:21001330:C:G	W54C	1.000
22:21001332:A:G	W54R	1.000
22:21001332:A:T	W54R	1.000
22:21001375:C:A	W39C	1.000
22:21001375:C:G	W39C	1.000
22:21001377:A:G	W39R	1.000
22:21001377:A:T	W39R	1.000
22:21001836:G:C	H26D	1.000
22:21001836:G:T	H26N	1.000
22:21001837:G:C	F25L	1.000
22:21001837:G:T	F25L	1.000
22:21001838:A:C	F25C	1.000
22:21001838:A:G	F25S	1.000

dbSNP variants (sampled 300 via entrez): RS1000361993 (22:21001756 C>T), RS1000682653 (22:21000487 C>A,G), RS1001657904 (22:21002246 C>G,T), RS1002270665 (22:21003831 G>A,T), RS1002352034 (22:20999389 G>A), RS1002425686 (22:20999715 G>A), RS1002821780 (22:20998611 G>A), RS1002859485 (22:20998962 CTT>C), RS1002895536 (22:20998709 A>G), RS1002923853 (22:21002990 A>G), RS1002996533 (22:21002801 G>A), RS1003227580 (22:20999809 G>A), RS1003672449 (22:21004074 A>G), RS1004193901 (22:21003849 G>A), RS1004391732 (22:20999749 C>G,T)

Disease associations

OMIM: gene MIM:609518 | disease phenotypes: MIM:608363, MIM:605275, MIM:615670, MIM:616564

GenCC curated gene-disease

Mondo (5): chromosome 22q11.2 microduplication syndrome (MONDO:0012020), Noonan syndrome 2 (MONDO:0011531), LZTR1-related schwannomatosis (MONDO:0014299), Noonan syndrome 10 (MONDO:0014693), hereditary neoplastic syndrome (MONDO:0015356)

Orphanet (4): 22q11.2 duplication syndrome (Orphanet:1727), Inherited cancer-predisposing syndrome (Orphanet:140162), Noonan syndrome (Orphanet:648), Full schwannomatosis (Orphanet:93921)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D009386	Neoplastic Syndromes, Hereditary	C04.700; C16.320.700
C567224	Chromosome 22q11.2 Microduplication Syndrome (supp.)
C548081	Noonan Syndrome 2 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

21 total (human), top 21 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Cadmium Chloride	decreases expression	2
GSK-J4	decreases expression	1
sodium arsenite	decreases expression	1
zinc chromate	decreases expression, increases abundance	1
ferrous chloride	decreases expression	1
chromium hexavalent ion	increases abundance, decreases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	decreases expression, decreases reaction	1
(4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II)	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Atrazine	decreases expression	1
Vehicle Emissions	decreases reaction, decreases expression	1
Cisplatin	affects cotreatment, increases expression	1
Selenium	increases expression	1
Smoke	decreases expression	1
Dronabinol	decreases expression	1
Thiram	decreases expression	1
Urethane	decreases expression	1
Copper Sulfate	decreases expression	1
Acrylamide	decreases expression	1
Particulate Matter	decreases expression, decreases reaction	1

Cellosaurus cell lines

13 cell lines: 9 transformed cell line, 3 embryonic stem cell, 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A7L7	SEES3-1V human THAP7, clone1	Embryonic stem cell	Male
CVCL_A7L8	SEES3-1V human THAP7, clone2	Embryonic stem cell	Male
CVCL_A7L9	SEES3-1V human THAP7, clone3	Embryonic stem cell	Male
CVCL_B2IH	Abcam HeLa THAP7 KO	Cancer cell line	Female
CVCL_B5DS	HEK293 THAP7DCC #7	Transformed cell line	Female
CVCL_B5DT	HEK293 THAP7DCC #27	Transformed cell line	Female
CVCL_B5DU	HEK293 THAP7DCC #36	Transformed cell line	Female
CVCL_B5DV	HEK293 THAP7DCC #40	Transformed cell line	Female
CVCL_B5DW	HEK293 THAP7HBM #34	Transformed cell line	Female
CVCL_B5DX	HEK293 THAP7HBM #76	Transformed cell line	Female

Clinical trials (associated diseases)

29 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00001496	Not specified	COMPLETED	Establishment of Normal Breast Epithelial Cell Lines From Patients at High Risk for Breast Cancer
NCT00001898	Not specified	COMPLETED	Microarray Analysis for Human Genetic Disease
NCT00026884	Not specified	RECRUITING	Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
NCT02289326	Not specified	COMPLETED	Biomarker Monitoring in TP53 Mutation Carriers
NCT02958462	Not specified	RECRUITING	Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
NCT03160274	Not specified	RECRUITING	Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
NCT03426878	Not specified	COMPLETED	Cancer Health Assessments Reaching Many
NCT03857594	Not specified	ACTIVE_NOT_RECRUITING	Integrative Sequencing In Germline and Hereditary Tumours
NCT03973450	Not specified	UNKNOWN	Epidemiology of Pituitary Tumours: Prevalence of Associated Neoplasia
NCT03979612	Not specified	UNKNOWN	Evaluation of the Adhesion to the GENEPY Network
NCT04261972	Not specified	ACTIVE_NOT_RECRUITING	Cell-free DNA in Hereditary And High-Risk Malignancies 1
NCT04494945	Not specified	RECRUITING	Identifying and Caring for Individuals With Inherited Cancer Syndrome
NCT04541654	Not specified	RECRUITING	Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress
NCT04763915	Not specified	ACTIVE_NOT_RECRUITING	Improving Care After Inherited Cancer Testing
NCT05562778	Not specified	RECRUITING	Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment
NCT05664867	Not specified	RECRUITING	Implementation of Population Cancer Genetic Services in Federally Qualified Health Centers (FQHC)
NCT05721326	Not specified	COMPLETED	Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition
NCT06096688	Not specified	RECRUITING	Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction
NCT06654466	Not specified	RECRUITING	Closing the GAPS: Guideline Adherence, Prevention and Surveillance in Hereditary Cancer
NCT06708429	Not specified	RECRUITING	Lynch Syndrome X-Talk of Enteral Mucosa With Immune System
NCT06726642	Not specified	RECRUITING	CfDNA in Hereditary And High-risk Malignancies 2
NCT06914726	Not specified	ENROLLING_BY_INVITATION	Patient Centered Clinical Decision Support for Hereditary Cancer Syndromes
NCT06927947	Not specified	RECRUITING	Navigation Interventions to Improve Cascade Genetic Testing Among Relatives of Patients With Hereditary Cancer Syndromes
NCT06999954	Not specified	RECRUITING	Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform
NCT07052266	Not specified	RECRUITING	Trial of Combined Obstetric Carrier Screening and Hereditary Cancer Screening
NCT07195071	Not specified	RECRUITING	Feasibility Trial of Combination of Obstetrical Carrier Screening and Hereditary Cancer Screening
NCT07378423	Not specified	RECRUITING	Questionnaire on Congenital Cancer Signs Through Self-Assessment
NCT07381985	Not specified	ENROLLING_BY_INVITATION	Strategy for Management of Patients With Hereditary Cancer Syndromes (HCS) in a Rural Environment
NCT07542405	Not specified	NOT_YET_RECRUITING	A Web-Based Program (Kindred) to Improve the Understanding of Genetic Cancer Risk and Cancer Genetic Testing in African American Families